InterventionsHuman trial4,401 participantsRandomised trialPlacebo-controlled

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

Nephrology, Dialysis, Transplantation

The paper

Emily K. Yeung, Amanda Siriwardana, Luke Buizen,

Arthur H. C. Tang, Min Jun, Kevan Roy Polkinghorne, Sydney C.W. Tang, Sradha S. Kotwal, Clare Gabrielle Arnott, Adeera Levin, Meg Jardine, Soo Kun Lim, Vivekanand Jha, Kenneth W. Mahaffey, Vlado Perkovic, Hiddo J.L. Heerspink,

Brendon Lange Neuen

The Royal Melbourne Hospital · Royal North Shore Hospital

Nephrology, Dialysis, Transplantation · 4 Sep 2026

doi.org/10.1093/ndt/gfag203 PubMed 42695992

Lower physical performance links to heart failure and death in CKD
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
NMR metabolomics improves prediction of cardiometabolic diseases
medRxiv · 4 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026